01.17.17 By Sanofi Le Hub
On Wednesday, January 18, 2017, during the World Economic Forum in Davos, Switzerland, Sanofi together with 21 of our industry competitors and peers, the World Bank and the Union for International Cancer Control (UICC) launched the Access Accelerated Initiative (AAI)— a new coalition to address the burden of non-communicable diseases (NCDs) in low and lower-middle income countries.
NCDs have emerged as a major public health threat over the last few decades and are now at a point of crisis. It is estimated that NCDs – including cancers, cardiovascular diseases, chronic respiratory diseases, diabetes and mental health disorders – are responsible for as many as 36 million deaths each year. According to the World Health Organization1, almost three-quarters of NCD-related deaths occur in low- and middle-income countries, where access to healthcare is limited.
Through the launch of the Access Accelerated Initiative (AAI), the companies are committing their resources and expertise towards achieving one of the UN Sustainable Development Goals: to reduce premature deaths from NCDs by one-third by 2030. Under the Access Accelerated coalition, Sanofi will work together with 21 industry partners, the World Bank and the UICC to start with, to:
– share best practice gathered from our longstanding commitments and own projects;
– design and set up targeted pilot projects, with the objective of scaling them up in time;
– identify what is working and what isn’t so that we can collectively improve on ourefforts to overcome barriers to primary care delivery for NCD patients;
– nurture disease-specific partnerships, starting with the development of effective, sustainable cancer care delivery models in a number of pilot cities.
What’s particularly interesting is that our efforts will be evaluated with the support of independent experts at Boston University to establish a framework for progress, measure effectiveness and deliver ongoing reporting. This means that we will be able to review and assess our impact on a regular basis, making any adjustments necessary and providing a solid platform for engagement at local and national level.
“Today, we have the means to prevent and treat many forms of non-communicable diseases (NCDs), yet 36 million lives are taken every year, most of which in low and middle income countries. Sanofi, a global leader in research and development of innovative treatments for NCDs, is acting every day to ensure more patients get access to the treatments they need. That’s why we are proud to be supporting the industry-wide Access Accelerated initiative. Because we believe it is only through collaboration that we can hope to build a future where no one dies prematurely from a treatable, preventable disease.”
Olivier Brandicourt, Chief Executive Officer, Sanofi
Sanofi is proud to be a founding partner of AAI. Our active participation in the Access Accelerated Initiative is rooted in our long-standing efforts to help ensure that appropriate and innovative treatments are made accessible to all those who need them, including through our own Access to Medicines programs.
Through our Access to Medicines’ commitment – which spans 15 years in infectious diseases and 10 years in mental health – Sanofi has been collaborating with governments, public authorities and local communities to improve access to healthcare in some of the poorest countries. Sanofi has a longstanding commitment to supporting low and middle income countries in building sustainable healthcare access and delivery systems through programs that focus on capacity building for vaccines, neglected tropical diseases, rare diseases and infectious diseases.
We are convinced that the Access Accelerated Initiative is well placed to bring us closer to reducing the burden of NCDs in low and lower middle income countries.
FAST – Fight Against Stigma (mental health)
– A joint World Association of Social Psychiatry initiative since 2008 to improve access to mental healthcare in low and middle-income countries
– It has pilot programs in Bolivia, Cameroon, Madagascar, and Myanmar; with scaling-up projects working or earmarked for Morocco, Armenia and Mauritania.
“Sanofi is strongly committed to improving access to quality care for patients suffering from mental disorders in developing countries. Our actions are also aimed at combating discrimination against these patients and ensuring they are integrated in the health care system.”
Dr François Bompart, Head, Access to Medicines Department, Sanofi.
My Child Matters (childhood cancer)
– A collaboration with international and local organizations to expand access to cancer treatment
– It has 65 projects in 40 countries enabling treatment access for 50,000 children and training for 15,000 healthcare professionals.
“This program exists for a simple reason: give children around the world the same chance of getting treatment. In 10 years, we have achieved tangible results including decentralizing and harmonizing care in Paraguay, establishing a childhood cancer registry in Colombia, and establishing a retinoblastoma network in sub-Saharan Africa”.
Dr Anne Gagnepain-Lacheteau, Medical Director of the Sanofi Espoir Foundation
KiDS (kids and diabetes in school)
– A Sanofi partnership with the International Diabetes Federation and the International Society for Pediatric and Adolescent Diabetes to support children with type 1 diabetes, and raise awareness on healthy lifestyle among all schoolchildren.
– The aim is to work with partners and policymakers to introduce diabetes education into the national teachers’ curriculum.
“Sanofi is committed to sustainable solutions that improve the lives of people with diabetes everywhere – children included. We believe that initiatives such as KiDS are also essential for promoting healthy living at an early age, potentially helping in the prevention of type 2 diabetes.”
Antonio Tataranni – Head, Medical Affairs – Diabetes and Cardiovascular Business Unit – Sanofi
– An initiative supported by a number of pharmaceutical companies including Sanofi.
– The objective is to test the impact of differential pricing on NCD (cardiovascular conditions, type 2 diabetes, hypertension, childhood pneumonia) treatment in Ghana and the Philippines
– Focus on intra-country differential, or tiered, pricing – a system in which prices are set taking into consideration the different economic levels of patients within a country.
Learn more about Sanofi’s commitment against NCDs through the Access Accelerated Initiative on our CSR page.
Recommended by Sanofi Le Hub
10.20.17 By Sanofi Le Hub
10.18.17 By Sanofi Le Hub
10.12.17 By Sanofi Le Hub
08.09.17 | By Sanofi Le Hub
10.28.16 | By Sanofi Le Hub
10.24.16 | By Sanofi Le Hub
10.14.16 | By Sanofi Le Hub
10.07.16 | From WHO
09.29.16 | By Sanofi Le Hub
09.21.16 | By Sanofi Le Hub
09.15.16 | By Sanofi Le Hub
09.09.16 | By Sanofi Le Hub
09.01.16 | By Sanofi Le Hub
08.24.16 | By Sanofi.fr
08.12.16 | By Sanofi Le Hub
08.03.16 | By Sanofi Le Hub
07.26.16 | By Sanofi Le Hub
07.21.16 | By Sanofi Le Hub
07.01.16 | From BIOtechNOW
06.27.16 | By Sanofi Le Hub
06.21.16 | By Sanofi Le Hub
06.15.16 | By Sanofi Le Hub